Advantis Corporation (OTCMKTS:ADVT) Rolls Out Cannabis Products for Pain Relief

0
170

Advantis Corporation (OTCMKTS:ADVT) shares rose 13.56% to $0.0335 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.03. The company has a market cap of $13.96 million at 465.48 million shares outstanding.

Advantis Corporation is a company that is focused on helping people take control of their health and pain management needs. It does this through partnerships innovative companies in the nutraceutical and alternative health care industries, making the company uniquely positioned to provide the guidance and support to assist in delivering products and services that address the needs of these individuals. Their strategy involves acquiring ownership in developing companies and providing consultation to improve product lines, expand distribution channels, and heighten brand value. Advantis concentrates on healthcare and pain management sectors that forecast staggering growth, identifying partners that possess the potential to capitalize on this trend.

In a press release yesterday, Advantis Corporation announced that it begins distribution of topical cannabis roll-on and Tinctures to treat pain conditions. In particular, Elixicure is a line of CBD dominant products used to treat pain without the psychoactive effects associated with THC.  Its pain relief roll-onis specially formulated, using the extract of the cannabis plant, which contains the principal cannabinoid CBD while the pain cream includes over 90% Certified Organic ingredients and is specially formulated with Counter-Irritants to block pain receptors and Salicylic Acids to provide a deep penetrating Aspirin-like relief.

Elixicure utilizes the purest, pharmaceutically derived essential oils and active ingredients to create products that are superior in quality than those available in the marketplace today, and we are very excited to add them to our rapidly growing portfolio of products,” said Advantis Corporation CEO Christopher Swartz in a recent press conference.

The company has been on an all-out media blitz to provide exposure to deliver attention to their progress and product lines. They have also tapped UFC Legend Kimo Leopoldo as a brand ambassador since many high-profile fighters have been lobbying to make CBD remedies legal.

My passion for fighting has been a painful one. The day-to-day grind in the gym as well as the battles in The Octagon left me with aches and pains. The doctors prescribe medicines that may help with this pain, but the side effects from those medicines outweigh the benefits. The Elixicure line of products have relieved my pain with zero side effects,” said Kimo.

In a previous announcement CEO Swartz hinted that “revenue is about to explode” as the company has several efforts lined up for 2017. He added that the company is poised to reach its highest revenue ever for the year and that this momentum can be sustained in the foreseeable future.

We have seen the problem with chronic pain conditions increase exponentially and with that, opiate misuse and addiction as well. I have personally seen all this happen and have observed (too many times) people whom have lost hope,” Swartz further explained, “I have been passionate about creating solutions to effectively treat the masses without the negative side effects associated with opioids. Elixcure is the answer, and we are excited beyond belief to share this remedy with everyone in need.”

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

LEAVE A REPLY

Please enter your comment!
Please enter your name here